
NK
Healthcare · Biotechnology · $3.55B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2021
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 4, 2021 | After the close | -0.18 | -0.30 | -66.7% |
| Nov 9, 2020 | After the close | -0.18 | -0.20 | -11.1% |
| Aug 7, 2020 | After the close | -0.19 | -0.20 | -5.3% |
| May 11, 2020 | After the close | -0.17 | -0.19 | -11.8% |
| Mar 25, 2020 | After the close | -0.20 | -0.16 | +20.0% |
| Nov 5, 2019 | After the close | -0.18 | -0.16 | +12.0% |
| Aug 6, 2019 | After the close | -0.23 | -0.17 | +26.5% |
| May 8, 2019 | After the close | -0.23 | -0.22 | +6.3% |
| Mar 13, 2019 | After the close | -0.31 | -0.22 | +30.1% |
| Nov 7, 2018 | After the close | -0.37 | -0.30 | +18.7% |
| Aug 6, 2018 | After the close | -0.37 | -0.35 | +6.0% |
| May 7, 2018 | After the close | -0.34 | -0.35 | -2.8% |
| Mar 12, 2018 | After the close | -0.33 | -0.31 |
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf…
| +6.9% |